(Q35116892)

English

Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: A targeted approach to enhance apoptosis

scientific article published on April 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis (English)

1 reference

Europe PubMed Central

6 August 2017

Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: A targeted approach to enhance apoptosis (English)

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

author name string

Stanley R. Frankel

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12720157

28 December 2023

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12720157

28 December 2023

publication date

1 April 2003

1 reference

Europe PubMed Central

6 August 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0093775403700980?httpAccept=text/xml

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

https://api.elsevier.com/content/article/PII:S0093775403700980?httpAccept=text/plain

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Seminars in Oncology

1 reference

Europe PubMed Central

6 August 2017

30

1 reference

Europe PubMed Central

6 August 2017

2

1 reference

Europe PubMed Central

6 August 2017

300-304

1 reference

Europe PubMed Central

6 August 2017

Apoptosis: a link between cancer genetics and chemotherapy

1

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

From bench to clinic with apoptosis-based therapeutic agents

3

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

A matter of life and death

4

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

BCL-2 family members and the mitochondria in apoptosis

5

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization

6

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death

7

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Dysregulation of apoptosis in cancer

9

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Mechanisms of apoptosis

10

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression.

11

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Genetic analysis of chemoresistance in primary murine lymphomas.

12

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Immunophenotypic analysis of Waldenstrom's macroglobulinemia

13

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells

14

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Developing diagnostic criteria in Waldenstrom's macroglobulinemia

15

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis

17

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines

18

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia

19

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease

20

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX

21

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques

22

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).

23

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Antisense oligonucleotides: basic concepts and mechanisms

25

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Antisense oligonucleotides: promise and reality.

26

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

27

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

29

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide

30

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice

32

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides

35

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

36

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer

38

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

40

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

41

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

45

1 reference

10.1053/SONC.2003.50041

https://api.crossref.org/works/10.1053/SONC.2003.50041

28 December 2023

Identifiers

10.1053/SONC.2003.50041

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35116892&oldid=2039259187"